Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › LEADER

LEADER

Liraglutide · T2D at high CV risk

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Liraglutide
Population
T2D at high CV risk
Official title
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2010-08 → 2015-12
Participants
9341
Registry
NCT01179048

Cardiovascular and kidney outcomes

LEADER liraglutide 1.8 mg vs placebo · T2D at high CV risk · n = 9340 · 2016 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of CV death, nonfatal (including silent) MI, or nonfatal stroke
0.870.78–0.97608 vs 694verified
Cardiovascular death
Death from cardiovascular causes
0.780.66–0.93219 vs 278verified
All-cause death
Death from any cause
0.850.74–0.97381 vs 447verified
Myocardial infarction
Myocardial infarction (fatal or nonfatal); not prespecified analysis
0.860.73–1.00292 vs 339verified
Stroke
Stroke (fatal or nonfatal); not prespecified analysis
0.860.71–1.06173 vs 199verified
Hospitalisation for heart failure
Hospitalization for heart failure
0.870.73–1.05218 vs 248verified
Kidney composite
Nephropathy: new-onset persistent macroalbuminuria, doubling of serum creatinine with eGFR <=45, continuous renal-replacement therapy, or death from renal disea
0.780.67–0.92268 vs 337verified
Expanded MACE (MACE + HF hosp. + revasc. + UA)
Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina pectoris or heart failure
0.880.81–0.96948 vs 1062verified
Retinopathy complications
Retinopathy: need for retinal photocoagulation or treatment with intravitreal agents, vitreous hemorrhage, or onset of diabetes-related blindness
1.150.87–1.52106 vs 92verified
Coronary revascularisation
Coronary revascularization
0.910.80–1.04405 vs 441verified
Hospitalisation for unstable angina
Hospitalization for unstable angina pectoris
0.980.76–1.26122 vs 124verified
Verbatim quotes (11)
  • 3-point MACE · Abstract; Results, Cardiovascular Outcomes; Table 1
    The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% CI, 0.78 to 0.97
  • Cardiovascular death · Results, Cardiovascular Outcomes; Table 1
    Death from cardiovascular causes occurred in fewer patients in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93
  • All-cause death · Results, Cardiovascular Outcomes; Table 1
    The rate of death from any cause was also lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97
  • Myocardial infarction · Table 1
    Myocardial infarction § 292 (6.3) 1.6 339 (7.3) 1.9 0.86 (0.73–1.00) 0.046
  • Stroke · Table 1
    Stroke § 173 (3.7) 1.0 199 (4.3) 1.1 0.86 (0.71–1.06) 0.16
  • Hospitalisation for heart failure · Table 1
    Hospitalization for heart failure 218 (4.7) 1.2 248 (5.3) 1.4 0.87 (0.73–1.05) 0.14
  • Kidney composite · Table 1; Results, Microvascular Outcomes
    Nephropathy 268 (5.7) 1.5 337 (7.2) 1.9 0.78 (0.67–0.92) 0.003
  • Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 1
    Expanded composite outcome ‡ 948 (20.3) 5.3 1062 (22.7) 6.0 0.88 (0.81–0.96)
  • Retinopathy complications · Table 1, microvascular outcomes
    Retinopathy 106 (2.3) 0.6 92 (2.0) 0.5 1.15 (0.87–1.52)
  • Coronary revascularisation · Table 1
    Coronary revascularization 405 (8.7) 2.3 441 (9.4) 2.5 0.91 (0.80–1.04)
  • Hospitalisation for unstable angina · Table 1
    Hospitalization for unstable angina pectoris 122 (2.6) 0.7 124 (2.7) 0.7 0.98 (0.76–1.26)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: LEADER. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/leader/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.